论文部分内容阅读
目的:探讨山仙颗粒配合介入疗法治疗中晚期肝癌的临床疗效。方法:对70例原发性肝癌患者行经皮动脉穿刺肝动脉灌注化疗栓塞术,并配合山仙颗粒治疗。结果:治疗组部分缓解率42.86%,对照组25.71%,两组比较有显著性差异(P<0.05);卡氏评分治疗组治疗后较治疗前提高14例(40%),降低3例(8.57%),对照组治疗后较治疗前提高7例(20%),降低8例(22.86%),两组间生活质量提高率和降低率差异均有显著性(P<0.05);治疗组1、2、3年生存率分别为65.71%、48.57%和34.29%,而对照组分别为51.43%、34.29%和17.14%,两组比较均有非常显著性差异P均<0.05。结论:山仙颗粒配合介入治疗中晚肝癌,具有减毒增效的作用。
Objective: To investigate the clinical effects of Shanxian granule combined with interventional therapy in the treatment of advanced liver cancer. Methods: Seventy patients with primary hepatic carcinoma underwent percutaneous transhepatic arterial chemoembolization and shanxian granule therapy. Results: The partial remission rate was 42.86% in the treatment group and 25.71% in the control group, with significant difference between the two groups (P <0.05). In the treatment group, the cardiograph score increased by 14 (40%) and decreased by 3 (P <0.05). In the control group, 7 cases (20%) and 8 cases (22.86%) were improved after treatment compared with before treatment, the difference between the two groups was significant (P <0.05) The 1, 2, 3-year survival rates were 65.71%, 48.57% and 34.29%, respectively, while those in the control group were 51.43%, 34.29% and 17.14% respectively. There was a significant difference between the two groups (all P <0.05). Conclusion: Shanxian granule with interventional treatment of advanced hepatocellular carcinoma, with attenuated synergistic effect.